11.7
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blocker…
Calcium channel blockers, or CCBs, and ranolazine are two important types of drugs used to treat angina pectoris.
CCBs block calcium channels in cardiac and smooth muscle cells and inhibit the influx of calcium ions, leading to vasodilation and reduced myocardial oxygen demand.
CCBs comprise dihydropyridines, such as nifedipine, phenylalkylamines, such as verapamil, and benzothiazepines such as diltiazem.
All CCBs that are administered orally undergo extensive metabolism. Drugs like verapamil and diltiazem can also be given via intravenous routes.
Side effects of CCBs include headache, dizziness, and peripheral edema.
Sodium-channel blockers like ranolazine inhibit the late-phase sodium current in cardiac cells during repolarization, which prevents calcium entry via the sodium-calcium exchanger. As a result, intracellular levels of sodium and calcium decrease, relaxing the cardiac muscle and improving coronary blood flow.
Ranolazine is well absorbed when taken orally and is primarily metabolized by CYP3A enzymes.
Common side effects of ranolazine include dizziness, headache, constipation, and nausea.
View the full transcript and gain access to JoVE Core videos
Q1: How do calcium channel blockers work to treat angina?
Calcium channel blockers (CCBs) block calcium channels in cardiac and smooth muscle cells, inhibiting calcium ion influx. This causes vasodilation and reduces myocardial oxygen demand, relieving angina symptoms. CCBs include dihydropyridines like nifedipine, phenylalkylamines like verapamil, and benzothiazepines like diltiazem, all used to manage ischemic heart disease.
Q2: What are the main types of calcium channel blockers?
Calcium channel blockers comprise three classes: dihydropyridines such as nifedipine, phenylalkylamines such as verapamil, and benzothiazepines such as diltiazem. All undergo extensive metabolism when administered orally. Verapamil and diltiazem can also be given intravenously, offering flexible dosing options for acute and chronic angina management.
Q3: How does ranolazine differ from calcium channel blockers in treating angina?
Ranolazine is a sodium-channel blocker that inhibits late-phase sodium current during cardiac repolarization, preventing calcium entry via the sodium-calcium exchanger. This reduces intracellular sodium and calcium levels, relaxing cardiac muscle and improving coronary blood flow through a distinct mechanism from CCBs that block calcium channels directly.
Q4: What side effects are associated with calcium channel blockers?
Common side effects of calcium channel blockers include headache, dizziness, and peripheral edema. These effects result from vasodilation and fluid retention in tissues. Most patients tolerate CCBs well, though side effects may require dose adjustment or switching to alternative antianginal medications in some clinical cases.
Q5: How is ranolazine metabolized in the body?
Ranolazine is well absorbed when taken orally and is primarily metabolized by CYP3A enzymes in the liver. This metabolic pathway is important for drug interactions, as inhibitors or inducers of CYP3A can affect ranolazine levels and efficacy in treating angina pectoris symptoms.
Q6: What are the common side effects of ranolazine?
Common side effects of ranolazine include dizziness, headache, constipation, and nausea. These effects are generally mild and manageable with continued use. Ranolazine offers an alternative for angina patients who cannot tolerate or respond adequately to other antianginal agents like calcium channel blockers.
Q7: Why can verapamil and diltiazem be administered by multiple routes?
Verapamil and diltiazem can be given orally or intravenously, unlike dihydropyridines, providing treatment flexibility. Intravenous administration allows rapid onset for acute angina episodes, while oral forms provide maintenance therapy. This dual-route capability makes them versatile antianginal agents in both acute and chronic management scenarios.